Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Ordinary Shares, CHF 0.01 par value per share
-
Shares outstanding
-
57,458,694
-
Total 13F shares
-
4,978,440
-
Share change
-
+1,484,897
-
Total reported value
-
$94,739,711
-
Price per share
-
$19.03
-
Number of holders
-
20
-
Value change
-
+$28,331,355
-
Number of buys
-
18
-
Number of sells
-
3
Institutional Holders of Oculis Holding AG - Ordinary Shares, CHF 0.01 par value per share (OCS) as of Q1 2025
As of 31 Mar 2025,
Oculis Holding AG - Ordinary Shares, CHF 0.01 par value per share (OCS) was held by
20 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,978,440 shares.
The largest 10 holders included
Pivotal bioVenture Partners Investment Advisor LLC, Aberdeen Group plc, Nan Fung Group Holdings Ltd, SR One Capital Management, LP, Alyeska Investment Group, L.P., ACUTA CAPITAL PARTNERS, LLC, UBS Group AG, Compagnie Lombard Odier SCmA, BANK OF AMERICA CORP /DE/, and NORTHERN TRUST CORP.
This page lists
20
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.